381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies

Dose Escalation ◽

Fibroblast Growth ◽

Dose Escalation Study ◽

Preliminary Results ◽

Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies

10.1158/1535-7163.targ-17-a098 ◽

2018 ◽

Cited By ~ 1

Author(s):

Mansoor Saleh ◽

Martin Gutierrez ◽

Vivek Subbiah ◽

David C. Smith ◽

Luis Féliz ◽

...

Keyword(s):

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Preliminary Results ◽

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

European Journal of Cancer ◽

10.1016/s0959-8049(12)72418-8 ◽

2012 ◽

Vol 48 ◽

pp. 191-192 ◽

Cited By ~ 26

Author(s):

P. ODonnell ◽

J.W. Goldman ◽

M.S. Gordon ◽

K. Shih ◽

Y.J. Choi ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Fibroblast Growth ◽

Dose Escalation Study

Abstract A103: Preliminary results of a phase 1 study of FP‐1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies

10.1158/1535-7163.targ-09-a103 ◽

2009 ◽

Cited By ~ 5

Author(s):

Anthony Tolcher ◽

Kyri Papadopoulos ◽

Jim Agnew ◽

John Marshall ◽

Carolyn Tanzola ◽

...

Keyword(s):

Growth Factor ◽

Phase 1 ◽

Fibroblast Growth ◽

Phase 1 Study ◽

Preliminary Results ◽

Abstract CT111: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies

10.1158/1538-7445.am2017-ct111 ◽

2017 ◽

Cited By ~ 2

Author(s):

Mansoor Saleh ◽

Martin E. Gutierrez ◽

Vivek Subbiah ◽

David C. Smith ◽

Ekaterine Asatiani ◽

...

Keyword(s):

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Preliminary Results ◽

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(00)00988-8 ◽

2000 ◽

Vol 36 (7) ◽

pp. 2132-2139 ◽

Cited By ~ 165

Author(s):

Roger J Laham ◽

Nicholas A Chronos ◽

Marilyn Pike ◽

Mark E Leimbach ◽

James E Udelson ◽

...

Keyword(s):

Heart Disease ◽

Growth Factor ◽

Ischemic Heart Disease ◽

Phase I ◽

Dose Escalation ◽

Fibroblast Growth ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

Faculty Opinions recommendation of Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1083008.535984 ◽

2007 ◽

Author(s):

Per Aspenberg

Keyword(s):

Growth Factor ◽

Dose Escalation ◽

Human Fibroblast ◽

Bone Repair ◽

Prospective Trial ◽

Local Application ◽

Fibroblast Growth Factor 2 ◽

Fibroblast Growth

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies

Pharmacology Research & Perspectives ◽

10.1002/prp2.906 ◽

2021 ◽

Vol 10 (1) ◽

Author(s):

Xiaohua Gong ◽

Tao Ji ◽

Xiang Liu ◽

Xuejun Chen ◽

Swamy Yeleswaram

Keyword(s):

Growth Factor ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Cardiac Safety ◽

Advanced Malignancies ◽

Receptor Inhibitor

Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

10.1158/1535-7163.targ-19-a078 ◽

2019 ◽

Cited By ~ 1

Author(s):

Vivek Subbiah ◽

Minal Barve ◽

Nicholas O. Iannotti ◽

Martin Gutierrez ◽

David C. Smith ◽

...

Keyword(s):

Growth Factor ◽

Combination Therapy ◽

Phase 1 ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Association of fibroblast growth factor 21 plasma levels with neonatal sepsis: preliminary results

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm-2018-0914 ◽

2019 ◽

Vol 57 (5) ◽

pp. e83-e85

Author(s):

Tania Siahanidou ◽

Alexandra Margeli ◽

Vasiliki Bourika ◽

Ioannis Papassotiriou

Keyword(s):

Growth Factor ◽

Neonatal Sepsis ◽

Plasma Levels ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Preliminary Results

Efficacy of recombinant human fibroblast growth factor 2 impregnated absorbable collagen membrane in the treatment of Miller's Class I and II gingival recession defects Preliminary results from the first in human clinical trial

Journal of Indian Society of Periodontology ◽

10.4103/jisp.jisp_76_20 ◽

2020 ◽

Vol 24 (6) ◽

pp. 541

Author(s):

Yarabham Chakravarthy ◽

RampalliViswa Chandra ◽

Kidambi Sneha ◽

Sabbani Pushpalatha

Keyword(s):

Clinical Trial ◽

Growth Factor ◽

Human Fibroblast ◽

Gingival Recession ◽

Fibroblast Growth Factor 2 ◽

Collagen Membrane ◽

Fibroblast Growth ◽

Human Clinical Trial ◽

Preliminary Results